Scrip: industry news and insights
26 Nov 2020
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
Many global pharmaceutical companies are well launched on their digital marketing “journeys” to engage with customers, but most of their Indian peers are still only at the beginner’s stage, says a new EY report, warning this could have critical implications in an increasingly competitive market.
Big Indian pharmaceutical players employ armies of salesmen to sell their drugs. But using salesmen as foot-soldiers to get physicians to prescribe their company’s drugs is fast becoming an outdated marketing model, says a just-released EY report.
Digital technologies now are the driving force in a rapidly shifting healthcare landscape with tech-aware doctors relying far less on pharmaceutical sales representatives and more on new independent online channels for information, says the report entitled “Reinventing pharma sales and marketing through digital in India.”
Nowadays, marketing “is more than just selling the pill,“ Sriram Shrinivasan, EY global life science emerging markets and generics leader, told Scrip.
Digital disruption globally has shaken industries from music and retail to travel and since 2000 has led to 52% of Fortune 500 companies becoming bankrupt, being acquired or going out of business, the report warns.
The Indian government, under Prime Minister Narendra Modi, has been aggressively pushing digitization in all areas of the economy from banking and retail to taxation.
Still, most Indian pharmaceutical companies remain at the early stages of digital adoption even as worldwide drug companies are moving — albeit cautiously as they look at factors such as return on investment (ROI) — toward being “digital practitioners,” the global consultancy says. (Also see "As Digital Channels Grow In Importance, AZ, Lilly, GSK Seen As Key Engagers" - Scrip, 12 Jul, 2017.)
According to a five-point digital-maturity scale developed by EY, some 93% of Indian pharma companies fall into the early-stage category and are yet to develop any clear digital strategy and have limited digital channels to find and engage customers.
“We compared what Indian companies are doing with regard to digitization to what global companies are doing and there is a significant gap,” said Shrinivasan.
There are more than 600,000 medical sales representatives in India, according to industry estimates, and they have long been considered as being among the greatest assets of Indian pharmaceutical firms. There is always a clutch of young men with bulging briefcases in doctors’ consulting rooms, waiting for a chance to make their pitch.
But only 11% of healthcare professionals in India now prefer in-person visits from a company representative, says a 2016 study by Health Link Dimensions2. Time-squeezed doctors, large private healthcare chains and increasingly online savvy patients, want Internet platforms to provide clinical information.
Already, there are a host of online communities for sharing patient experiences, apps and sensors to monitor the impact of therapy on a patient’s daily life and data aggregation and analysis to generate insights into drug efficacy and safety. Experts say pharma companies must rapidly build their own digital capabilities if they want to remain the main source of authority on product performance. “Data needs to become the currency of marketing,” the report says.
Looking at the US experience gives an idea of how digital is transforming the way the healthcare industry does business. Nearly 70% of US consumers use an online channel to manage health and wellness, more than 50% of US healthcare providers are digital “omnivores” using three or more connected devices professionally, and one in five of the top pharma companies now has a chief digital officer or equivalent position, and many others are creating senior management digital roles, according to a recent McKinsey report. (Also see "Six Questions For McKinsey's Fox On Pharma's Digital Struggle" - Scrip, 28 Oct, 2016.)
“The rules of engagement need to be redefined (in India),” says the EY report, which foresees the advent of “super consumers” and corporate hospital chains being at the core of drug-purchase decisions. The report suggests physicians’ role being “at the center of the pharma ecosystem may become a thing of the past.”
“Companies are getting FDA approval for their apps to help patients that will be a paradigm change in the way medicine is sold and practiced,” noted Shrinivasan. “You have an Alphabet (Google) working with GSK (to develop bio-electronic medicines)… That is totally disruptive.”
EY says 53% of Indian pharmaceutical companies are at the “beginners” stage with no digital marketing strategy at all in place and limited use of technology to capture interaction of sales representatives with physicians and other customers. A further 40% of companies have limited channels of customer digital engagement.
There are a just a few companies in what EY calls the “explorers” category, which have partly defined their digital strategies and are looking at ways to scale up to digitally link back-ends and front-ends and offer omni-channel interaction with customers.
Many of the key hurdles to digital advancement are not technological, but organizational, cultural and regulatory. In the EY report, 67% of the pharmaceutical executives surveyed cited “people resistance,” 80% cited lack of value proposition in solutions, 75% cited lack of authentic and sufficient data and 60% cited physicians’ mindsets and inertia as barriers.
“In our conversation with the companies, it was clear that they viewed making the move to digitization as very important… the technology, ambition and the desire is there. But there is a culture change that’s required. There are a number of barriers out there and they exist across the company hierarchy,” said Shrinivasan.
Indian pharma companies will have to create “hybrid” marketing teams including sales, medical, training and supply chain specialists to “seamlessly cater” to customer needs, the report says.
EY says Indian companies will also need to adopt a “fail fast and fail cheap” approach to allow quick learning cycles.
“The next three-to-four years will be crucial for companies to get out of their comfort zone and embrace disruption to avoid being disrupted… the strategic moves that companies make today will determine their survival,” the report says.
Scrip: industry news and insights
By Brian Yang 25 Nov 2020
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine...
Scrip: industry news and insights
By Anju Ghangurde 25 Nov 2020
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies...
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: